News
BII supports three international start-ups developing pioneering science in the therapeutics and health tech space
BII today announces its investment into three international start-up companies from the UK, Germany, and Finland.
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation (“CDE”) for its Investigational New Drug (“IND”) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) in mainland China.
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its upsized public offering of 14,260,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs.
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona…
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Ensifentrine met primary and secondary endpoints of evaluating…
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Statistically significant improvements in key measures of lung…
F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim
New Investment from Forbion and Sofinnova Partners
MANCHESTER,…
NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule…
Versameb to present at the BIO Asia-Taiwan Conference
Versameb AG (“Versameb”), a pre-clinical stage company focused…
Vicebio launched by medicxi to advance the Molecular Clamp technology and develop next generation RSV vaccine
Focused on delivering highly effective vaccines against life-threatening…
Doug Kohrs appointed to Sequana Medical Board of Directors
Highly experienced US medtech leader brings more than 40 years’…
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development:
…
Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans
FDA clarifies Phase 3 and US registration pathway for XF-73…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
Recognition of commendable, longstanding dedication to the…
Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance
MAFTEST® analyses of the NSABP-B34 and AZURE landmark clinical…
Invizius Announces Appointment of Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet, to the Clinical Advisory Board
World leading expert and key opinion leader in nephrology
Glasgow,…
Declaration of conformity drawn up for Inbiomotion MAFTEST®
Barcelona, July 13 2022, On 13 May 2022, the conformity assessment…
Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi
Neuraxpharm, the central nervous system (CNS) specialist, to…
vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Ronopterin significantly reduces lactate levels in brain microdialysate…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
